Prof Palumbo presents at ASCO 2016, initial findings from a pivotal phase III trial that showed that daratumumab added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.
Read the news story and watch the video interview for more.